Back to resources

Clinical trials

Clinical trial adherence monitoring

Clinical trial adherence monitoring helps study teams understand dosing behavior earlier, before missed or uncertain medication use weakens interpretation of trial data.

Published Last updated 6 min read

Separate reminder support from endpoint claims

Adherence monitoring can support trial operations, but it should not be described as proving clinical outcomes by itself. It provides context for whether the participant routine matched the protocol.

  • Use adherence data to support protocol visibility and follow-up.
  • Avoid treating device events as clinical efficacy evidence.
  • Define in advance how adherence data will be reviewed and interpreted.

Capture dosing events close to use

When intake events are captured near the point of use, study teams can better identify missed doses, late doses, and possible protocol deviations while there is still time to support the participant.

  • Connect schedules to the protocol dosing plan.
  • Flag exceptions that require coordinator review.
  • Keep raw device signals separate from confirmed clinical judgments.

Operational adherence data is most useful when it is timely, interpretable, and tied to a planned response.

Reduce participant burden

Monitoring should make participation easier, not heavier. Clear reminders, simple device interactions, and remote visibility can support participants without requiring unnecessary site visits.

  • Keep daily actions simple and predictable.
  • Use remote review for exceptions that can be handled without a visit.
  • Make the participant-facing routine match the actual dosing schedule.

Plan for missing or ambiguous data

Every monitoring approach has limits. Devices can be offline, participants can handle medication outside the expected routine, and not every signal means a dose was swallowed.

  • Document how missing data will be handled.
  • Let coordinators distinguish technical exceptions from participant behavior.
  • Use adherence data as one input in trial operations.

Fit monitoring to the protocol

Trials vary by medication, schedule, participant population, geography, and oversight needs. A modular adherence setup can adapt without rebuilding the whole workflow for every study.

  • Define whether the study needs reminders, tracking, alerts, exports, or all of them.
  • Align data access with sponsor, site, and participant roles.
  • Consider EU, Swiss, and local operational requirements before launch.

Sources used in this guide

These references provide context for medication safety, adherence workflows, and the healthcare settings discussed here. They are not Adherlo outcome claims.

Europe

EMA Clinical Trials Regulation

Verified regulatory context for EU/EEA trial submissions, CTIS transition obligations, and sponsor compliance workflows.

Open source

Europe

EMA Clinical Trials Information System

Single online platform used by sponsors and regulators for trial authorisation, oversight, and public transparency in the EU and EEA.

Open source

Switzerland

Swissmedic

Swissmedic is the Swiss medicines authority; clinical studies conducted in Switzerland must be notified to Swissmedic.

Open source

Global

WHO adherence to long-term therapies

Global adherence reference describing long-term therapy adherence as a multi-factor problem involving patient, therapy, social, economic, condition, and health-system factors.

Open source

Related resources

Plan adherence monitoring for a study

Adherlo supports clinical trial teams with smart devices, app workflows, and real-time adherence insights.